The Facts on TB

1.3 million

People died from TB in 2022

1 in 4

People globally infected with TB

10 Million

Fell ill with TB in 2022

The IMPAACT4TB Consortium and partners have been working towards delivering transformational change in the accessibility and use of Tuberculosis(TB) Preventive treatment(TPT) across high-burden TB project countries since the start of the project in 2018.

Funded by Unitaid, the IMPAACT4TB Consortium works in collaboration with the World Health Organisation(WHO) and focused primarily on providing safer, shorter TPT (3HP and 1HP) that is affordable and accessible to target populations: People living with HIV, children under 5 years and all household contacts.

The IMPAACT4TB Consortium members have exceptional experience in shaping markets, strengthening supply chain management and supporting National TB Programmes in high-burden countries.

Today, in Phase 2, we’re uncovering crucial evidence for often overlooked populations, such as children, pregnant women, and household contacts of TB cases. Our consortium has been instrumental in reshaping the TB landscape with short-course TPT, accelerating progress toward UNHLM targets and the ultimate goal of ending TB!

global impact of the impaact4tb consortium


Price of 3HP

The price dropped from $72 in 2017 to $14,25 in 2022 and $9,99 in 2023 for the FDC. 1HP is available at $17- $18.

Rifapentine Manufacturing Capacity

Increased from 180k patient courses in 2018 to over 4,5 million in 2023.

3HP Global procurement expansion

Over 4,5 million patient courses of rifapentine-based TB preventive treatments have been purchased across 78 countries. In total, 138 countries now have access to purchase 3HP.

Countries procuring 3HP

From one (1) country in 2018 to over seventy-eight (78) countries procuring 3HP in 2023.


impact worldwide

The IMPAACT4TB Project has moved into the next phase to generate more evidence for vulnerable and undeserved populations.

Watch our 3HP client stories and advocacy videos on our youtube channel here

Consortium Partners